Abstract
Rationale
The psychostimulant drugs cocaine and methamphetamine are potent indirect dopamine receptor agonists which act through similar but not identical mechanisms. Studies in humans have observed that a large proportion of those who chronically use these drugs experience psychotic symptoms. However, direct comparisons of psychotic symptom severity between cocaine and methamphetamine users are lacking.
Objectives
The goal of the present study was to directly compare severity of psychotic symptoms between cocaine- and methamphetamine-dependent individuals. Additionally, we sought to determine how concurrent cocaine + methamphetamine dependence would influence psychotic symptoms.
Methods
We recruited 153 polysubstance-using subjects meeting DSM-IV-TR criteria for cocaine dependence, 38 with methamphetamine dependence, and 32 with cocaine + methamphetamine dependence. Psychotic symptoms were assessed with the Positive and Negative Syndrome Scale (PANSS) and analyzed using a five-factor model. All participants were also assessed for physical and mental illnesses as well as recent substance use. Most subjects completed a comprehensive neurocognitive battery.
Results
While all three groups exhibited high total PANSS scores, the positive symptom subscale was significantly higher in the methamphetamine-dependent (17.03 ± 6.3) than the cocaine-dependent group (13.51 ± 4.12) and non-significantly higher (p = 0.08) than the cocaine + methamphetamine group (14.44 ± 5.50). Groups also differed on demographic variables, viral infection, and other indices of substance use, which were unlikely to account for the difference in positive symptoms. There were only modest differences between groups in neurocognitive function.
Conclusions
Methamphetamine dependence was associated with more severe positive symptoms of psychosis than cocaine dependence. Concurrent cocaine + methamphetamine dependence did not increase psychosis severity.
Similar content being viewed by others
References
Abi-Dargham A (2014) Schizophrenia: overview and dopamine dysfunction. J Clin Psychiatry 75:e31
Alam Mehrjerdi Z, Barr AM, Noroozi A (2013) Methamphetamine-associated psychosis: a new health challenge in Iran. Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences 21:30
Angrist B, Sathananthan G, Wilk S, Gershon S (1974) Amphetamine psychosis: behavioral and biochemical aspects. J Psychiatr Res 11:13–23
APA (2000) Diagnostic and statistical manual of mental disorders (4th ed., Text Revision), Washington, DC
Barr AM, Markou A (2005) Psychostimulant withdrawal as an inducing condition in animal models of depression. Neurosci Biobehav Rev 29:675–706
Barr AM, Markou A, Phillips AG (2002) A 'crash' course on psychostimulant withdrawal as a model of depression. Trends Pharmacol Sci 23:475–482
Barr AM, Panenka WJ, Macewan GW, Thornton AE, Lang DJ, Honer WG, Lecomte T (2006) The need for speed: an update on methamphetamine addiction. J Psychiatry Neurosci 31:301–313
Basso MR, Nasrallah HA, Olson SC, Bornstein RA (1998) Neuropsychological correlates of negative, disorganized and psychotic symptoms in schizophrenia. Schizophr Res 31:99–111
Batki SL, Harris DS (2004) Quantitative drug levels in stimulant psychosis: relationship to symptom severity, catecholamines and hyperkinesia. Am J Addict 13:461–470
Bechara A, Damasio AR, Damasio H, Anderson SW (1994) Insensitivity to future consequences following damage to human prefrontal cortex. Cognition 50:7–15
Bershad AK, Kirkpatrick MG, Seiden JA, de Wit H (2015) Effects of acute doses of prosocial drugs methamphetamine and alcohol on plasma oxytocin levels. J Clin Psychopharmacol 35:308–312
Bousman CA, McKetin R, Burns R, Woods SP, Morgan EE, Atkinson JH, Everall IP, Grant I (2015) Typologies of positive psychotic symptoms in methamphetamine dependence. Am J Addict 24:94–97
Brady KT, Lydiard RB, Malcolm R, Ballenger JC (1991) Cocaine-induced psychosis. J Clin Psychiatry 52:509–512
Brandt J, Benedict RH (2001) Hopkins verbal learning test—revised: professional manual. Psychological Assessment Resources
Busto U, Bendayan R, Sellers EM (1989) Clinical pharmacokinetics of non-opiate abused drugs. Clin Pharmacokinet 16:1–26
Camp DM, Browman KE, Robinson TE (1994) The effects of methamphetamine and cocaine on motor behavior and extracellular dopamine in the ventral striatum of Lewis versus Fischer 344 rats. Brain Res 668:180–193
Caspi A, Moffitt TE, Cannon M, McClay J, Murray R, Harrington H, Taylor A, Arseneault L, Williams B, Braithwaite A, Poulton R, Craig IW (2005) Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction. Biol Psychiatry 57:1117–1127
Cheng T, Johnston C, Kerr T, Nguyen P, Wood E, DeBeck K (2016) Substance use patterns and unprotected sex among street-involved youth in a Canadian setting: a prospective cohort study. BMC Public Health 16:4
Cheng WS, Garfein RS, Semple SJ, Strathdee SA, Zians JK, Patterson TL (2010) Binge use and sex and drug use behaviors among HIV(−), heterosexual methamphetamine users in San Diego. Subst Use Misuse 45:116–133
Emsley R, Rabinowitz J, Torreman M (2003) The factor structure for the Positive and Negative Syndrome Scale (PANSS) in recent-onset psychosis. Schizophr Res 61:47–57
Endicott J (1988) Best estimate clinical evaluation and diagnosis form (BECED). Department of Research Assessment and Training, New York State Psychiatric Institute, New York
Farrell M, Boys A, Bebbington P, Brugha T, Coid J, Jenkins R, Lewis G, Meltzer H, Marsden J, Singleton N, Taylor C (2002) Psychosis and drug dependence: results from a national survey of prisoners. Br J Psychiatry 181:393–398
Fleckenstein AE, Volz TJ, Riddle EL, Gibb JW, Hanson GR (2007) New insights into the mechanism of action of amphetamines. Annu Rev Pharmacol Toxicol 47:681–698
Fornito A, Zalesky A, Breakspear M (2015) The connectomics of brain disorders. Nat Rev Neurosci 16:159–172
Fowler JS, Volkow ND, Logan J, Alexoff D, Telang F, Wang GJ, Wong C, Ma Y, Kriplani A, Pradhan K, Schlyer D, Jayne M, Hubbard B, Carter P, Warner D, King P, Shea C, Xu Y, Muench L, Apelskog K (2008) Fast uptake and long-lasting binding of methamphetamine in the human brain: comparison with cocaine. NeuroImage 43:756–763
Fray PJ, Robbins TW, Sahakian BJ (1996) Neuorpsychiatyric applications of CANTAB. International Journal of Geriatric Psychiatry
Gicas KM, Giesbrecht CJ, Panenka WJ, Lang DJ, Smith GN, Vila-Rodriguez F, Leonova O, Jones AA, Barr AM, Procyshyn RM, Buchanan T, MacEwan GW, Su W, Vertinsky AT, Rauscher A, Honer WG, Thornton AE (2016) Structural brain markers are differentially associated with neurocognitive profiles in socially marginalized people with multimorbid illness. Neuropsychology
Gicas KM, Vila-Rodriguez F, Paquet K, Barr AM, Procyshyn RM, Lang DJ, Smith GN, Baitz HA, Giesbrecht CJ, Montaner JS, Krajden M, Krausz M, MacEwan GW, Panenka WJ, Honer WG, Thornton AE (2014) Neurocognitive profiles of marginally housed persons with comorbid substance dependence, viral infection, and psychiatric illness. J Clin Exp Neuropsychol 36:1009–1022
Gossop M, Darke S, Griffiths P, Hando J, Powis B, Hall W, Strang J (1995) The Severity of Dependence Scale (SDS): psychometric properties of the SDS in English and Australian samples of heroin, cocaine and amphetamine users. Addiction 90:607–614
Grant KM, LeVan TD, Wells SM, Li M, Stoltenberg SF, Gendelman HE, Carlo G, Bevins RA (2012) Methamphetamine-associated psychosis. J NeuroImmune Pharmacol 7:113–139
Harris D, Batki SL (2000) Stimulant psychosis: symptom profile and acute clinical course. Am J Addict 9:28–37
Harro J (2015) Neuropsychiatric adverse effects of amphetamine and methamphetamine. Int Rev Neurobiol 120:179–204
Hondebrink L, Meulenbelt J, Timmerman JG, van den Berg M, Westerink RH (2009) Amphetamine reduces vesicular dopamine content in dexamethasone-differentiated PC12 cells only following L-DOPA exposure. J Neurochem 111:624–633
Izawa J, Yamanashi K, Asakura T, Misu Y, Goshima Y (2006) Differential effects of methamphetamine and cocaine on behavior and extracellular levels of dopamine and 3,4-dihydroxyphenylalanine in the nucleus accumbens of conscious rats. Eur J Pharmacol 549:84–90
Jacobs E, Fujii D, Schiffman J, Bello I (2008) An exploratory analysis of neurocognition in methamphetamine-induced psychotic disorder and paranoid schizophrenia. Cogn Behav Neurol 21:98–103
Jones AA, Vila-Rodriguez F, Leonova O, Langheimer V, Lang DJ, Barr AM, Procyshyn RM, Smith GN, Schultz K, Buchanan T, Krausz M, Montaner JS, MacEwan GW, Rauscher A, Panenka WJ, Thornton AE, Honer WG (2015) Mortality from treatable illnesses in marginally housed adults: a prospective cohort study. BMJ Open 5:e008876
Jones AA, Vila-Rodriguez F, Panenka WJ, Leonova O, Strehlau V, Lang DJ, Thornton AE, Wong H, Barr AM, Procyshyn RM, Smith GN, Buchanan T, Krajden M, Krausz M, Montaner JS, Macewan GW, Nutt DJ, Honer WG (2013) Personalized risk assessment of drug-related harm is associated with health outcomes. PLoS One 8:e79754
Kahlig KM, Binda F, Khoshbouei H, Blakely RD, McMahon DG, Javitch JA, Galli A (2005) Amphetamine induces dopamine efflux through a dopamine transporter channel. Proc Natl Acad Sci U S A 102:3495–3500
Kalapatapu RK, Bedi G, Haney M, Evans SM, Rubin E, Foltin RW (2012) The subjective effects of cocaine: relationship to years of cocaine use and current age. Am J Drug Alcohol Abuse 38:530–534
Kalayasiri R, Gelernter J, Farrer L, Weiss R, Brady K, Gueorguieva R, Kranzler HR, Malison RT (2010) Adolescent cannabis use increases risk for cocaine-induced paranoia. Drug Alcohol Depend 107:196–201
Kalayasiri R, Kranzler HR, Weiss R, Brady K, Gueorguieva R, Panhuysen C, Yang BZ, Farrer L, Gelernter J, Malison RT (2006a) Risk factors for cocaine-induced paranoia in cocaine-dependent sibling pairs. Drug Alcohol Depend 84:77–84
Kalayasiri R, Sughondhabirom A, Gueorguieva R, Coric V, Lynch WJ, Morgan PT, Cubells JF, Malison RT (2006b) Self-reported paranoia during laboratory “binge” cocaine self-administration in humans. Pharmacol Biochem Behav 83:249–256
Kay SR, Fiszbein A, Opler LA (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13:261–276
Kay SR, Opler LA, Lindenmayer JP (1988) Reliability and validity of the positive and negative syndrome scale for schizophrenics. Psychiatry Res 23:99–110
Kuramoto SJ, Bohnert AS, Latkin CA (2011) Understanding subtypes of inner-city drug users with a latent class approach. Drug Alcohol Depend 118:237–243
Lecomte T, Mueser KT, MacEwan W, Thornton AE, Buchanan T, Bouchard V, Goldner E, Brink J, Lang D, Kang S, Barr AM, Honer WG (2013) Predictors of persistent psychotic symptoms in persons with methamphetamine abuse receiving psychiatric treatment. J Nerv Ment Dis 201:1085–1089
Leshner AI, Koob GF (1999) Drugs of abuse and the brain. Proceedings of the Association of American Physicians 111: 99–108
Lindenmayer JP, Kay SR, Friedman C (1986) Negative and positive schizophrenic syndromes after the acute phase: a prospective follow-up. Compr Psychiatry 27:276–286
Mach RH, Nader MA, Ehrenkaufer RL, Line SW, Smith CR, Gage HD, Morton TE (1997) Use of positron emission tomography to study the dynamics of psychostimulant-induced dopamine release. Pharmacol Biochem Behav 57:477–486
Mahoney JJ 3rd, Hawkins RY, De La Garza R 2nd, Kalechstein AD, Newton TF (2010) Relationship between gender and psychotic symptoms in cocaine-dependent and methamphetamine-dependent participants. Gender medicine 7:414–421
Mahoney JJ 3rd, Kalechstein AD, De La Garza R 2nd, Newton TF (2008) Presence and persistence of psychotic symptoms in cocaine- versus methamphetamine-dependent participants. Am J Addict 17:83–98
Matsumoto T, Kamijo A, Miyakawa T, Endo K, Yabana T, Kishimoto H, Okudaira K, Iseki E, Sakai T, Kosaka K (2002) Methamphetamine in Japan: the consequences of methamphetamine abuse as a function of route of administration. Addiction 97:809–817
McHorney CA, Ware JE Jr, Lu JF, Sherbourne CD (1994) The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care 32:40–66
McKetin R, Lubman DI, Baker AL, Dawe S, Ali RL (2013) Dose-related psychotic symptoms in chronic methamphetamine users: evidence from a prospective longitudinal study. JAMA psychiatry 70:319–324
McKetin R, McLaren J, Lubman DI, Hides L (2006) The prevalence of psychotic symptoms among methamphetamine users. Addiction 101:1473–1478
Medhus S, Mordal J, Holm B, Morland J, Bramness JG (2013) A comparison of symptoms and drug use between patients with methamphetamine associated psychoses and patients diagnosed with schizophrenia in two acute psychiatric wards. Psychiatry Res 206:17–21
Mooney M, Sofuoglu M, Dudish-Poulsen S, Hatsukami DK (2006) Preliminary observations of paranoia in a human laboratory study of cocaine. Addict Behav 31(7):1245–1251
O'Leary DS, Flaum M, Kesler ML, Flashman LA, Arndt S, Andreasen NC (2000) Cognitive correlates of the negative, disorganized, and psychotic symptom dimensions of schizophrenia. J Neuropsychiatry Clin Neurosci 12:4–15
Panenka WJ, Procyshyn RM, Lecomte T, MacEwan GW, Flynn SW, Honer WG, Barr AM (2013) Methamphetamine use: a comprehensive review of molecular, preclinical and clinical findings. Drug Alcohol Depend 129:167–179
Peralta V, Cuesta MJ (1994) Psychometric properties of the positive and negative syndrome scale (PANSS) in schizophrenia. Psychiatry Res 53:31–40
Satel SL, Edell WS (1991) Cocaine-induced paranoia and psychosis proneness. Am J Psychiatr 148(12):1708–1711
Schwartz K, Weizman A, Rehavi M (2006) The effect of psychostimulants on [3H]dopamine uptake and release in rat brain synaptic vesicles. J Neural Transm 113:1347–1352
Segal DS, Kuczenski R (1997a) Behavioral alterations induced by an escalating dose-binge pattern of cocaine administration. Behav Brain Res 88:251–260
Segal DS, Kuczenski R (1997b) Repeated binge exposures to amphetamine and methamphetamine: behavioral and neurochemical characterization. J Pharmacol Exp Ther 282:561–573
Simon SL, Domier CP, Sim T, Richardson K, Rawson RA, Ling W (2002) Cognitive performance of current methamphetamine and cocaine abusers. J Addict Dis 21:61–74
Smith MJ, Thirthalli J, Abdallah AB, Murray RM, Cottler LB (2009) Prevalence of psychotic symptoms in substance users: a comparison across substances. Compr Psychiatry 50:245–250
Sobell MB, Sobell LC, Klajner F, Pavan D, Basian E (1986) The reliability of a timeline method for assessing normal drinker college students’ recent drinking history: utility for alcohol research. Addict Behav 11(2):149–161
Tang VM, Lang DJ, Giesbrecht CJ, Panenka WJ, Willi T, Procyshyn RM, Vila-Rodriguez F, Jenkins W, Lecomte T, Boyda HN, Aleksic A, MacEwan GW, Honer WG, Barr AM (2015) White matter deficits assessed by diffusion tensor imaging and cognitive dysfunction in psychostimulant users with comorbid human immunodeficiency virus infection. BMC Res Notes 8:515
Trotta A, Murray RM, Fisher HL (2015) The impact of childhood adversity on the persistence of psychotic symptoms: a systematic review and meta-analysis. Psychol Med 45:2481–2498
Tsai J, Stroup TS, Rosenheck RA (2011) Housing arrangements among a national sample of adults with chronic schizophrenia living in the United States: a descriptive study. J Community Psychol 39:76–88
Vallersnes OM, Dines AM, Wood DM, Yates C, Heyerdahl F, Hovda KE, Giraudon I, Dargan PI (2016) Psychosis associated with acute recreational drug toxicity: a European case series. BMC Psychiatry 16:293
van der Plas EA, Crone EA, van den Wildenberg WP, Tranel D, Bechara A (2009) Executive control deficits in substance-dependent individuals: a comparison of alcohol, cocaine, and methamphetamine and of men and women. J Clin Exp Neuropsychol 31:706–719
Vergara-Moragues E, González-Saiz F, Lozano OM, Espinosa PB, Calderón FF, Bilbao-Acebos I, García MP, García AV (2012) Psychiatric comorbidity in cocaine users treated in therapeutic community: Substance-induced versus independent disorders. Psychiatry Res 200(2–3):734–741
Vila-Rodriguez F, Panenka WJ, Lang DJ, Thornton AE, Vertinsky T, Wong H, Barr AM, Procyshyn RM, Sidhu JJ, Smith GN, Buchanan T, Krajden M, Krausz M, Montaner JS, Macewan GW, Honer WG (2013) The hotel study: multimorbidity in a community sample living in marginal housing. Am J Psychiatry 170:1413–1422
Vorspan F, Brousse G, Bloch V, Bellais L, Romo L, Guillem E, Coeuru P, Lépine J-P (2012) Cocaine-induced psychotic symptoms in French cocaine addicts. Psychiatry Res 200(2–3):1074–1076
Wachtel SR, Ortengren A, de Wit H (2002) The effects of acute haloperidol or risperidone on subjective responses to methamphetamine in healthy volunteers. Drug Alcohol Depend 68:23–33
Waclawik K (2016) Predictors of one-year cognitive decline in a marginally housed, multimorbid sample Department of Psychology. Simon Fraser University, Burnaby, p 39
Wechsler D (2001) Wechsler Test of Adult Reading (WTAR). The Psychological Corporation
Willi TS, Barr AM, Gicas K, Lang DJ, Vila-Rodriguez F, Su W, Thornton AE, Leonova O, Giesbrecht CJ, Procyshyn RM, Rauscher A, MacEwan WG, Honer WG, Panenka WJ (2016a) Characterization of white matter integrity deficits in cocaine-dependent individuals with substance-induced psychosis compared with non-psychotic cocaine users. Addiction biology
Willi TS, Honer WG, Thornton AE, Gicas K, Procyshyn RM, Vila-Rodriguez F, Panenka WJ, Aleksic A, Leonova O, Jones AA, MacEwan GW, Barr AM (2016b) Factors affecting severity of positive and negative symptoms of psychosis in a polysubstance using population with psychostimulant dependence. Psychiatry Res 240:336–342
Willi TS, Lang DJ, Honer WG, Smith GN, Thornton AE, Panenka WJ, Procyshyn RM, Vila-Rodriguez F, Su W, Vertinsky AT, Leonova O, Rauscher A, MacEwan GW, Barr AM (2016c) Subcortical grey matter alterations in cocaine dependent individuals with substance-induced psychosis compared to non-psychotic cocaine users. Schizophr Res
Acknowledgements
The study was funded by the Canadian Institutes for Health Research (CBG-101827, MOP-137103) and the British Columbia Mental Health and Substance Use Services (an Agency of the Provincial Health Services Authority).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
In accordance to Tri-Council policy, the study was approved by the University of British Columbia Clinical Research Ethics Board. All participants provided written informed consent and received a modest honorarium for their time.
Conflicts of interest
Drs. Smith, Thornton, Panenka, Vila-Rodriguez, Leonova, Lang and MacEwan report no competing interests. Mr(s). Alexander, Gicas, Willi, Kim, Boyeva, and Jones report no competing interests.
Dr. Honer has received consulting fees or sat on paid advisory boards for: In Silico, Otsuka/Lundbeck, Roche and Eli Lilly; received honoraria from Rush University, University of Ottawa, University of Calgary, University of Hong Kong, British Columbia Health Authorities, the British Association for Psychopharmacology, and the Canadian Psychiatric Association; and received grants from the Canadian Institutes of Health Research (CIHR).
Dr. Procyshyn has received consulting fees from: Janssen, Lundbeck, Otsuka, Pfizer, and Sunovion and is on the speaker’s bureau for AstraZeneca, Janssen, Lundbeck, Otsuka, and Pfizer; and received grants from the Canadian Institutes of Health Research
Dr. Barr has received grant support from BMS Canada.
Rights and permissions
About this article
Cite this article
Alexander, P.D., Gicas, K.M., Willi, T.S. et al. A comparison of psychotic symptoms in subjects with methamphetamine versus cocaine dependence. Psychopharmacology 234, 1535–1547 (2017). https://doi.org/10.1007/s00213-017-4551-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00213-017-4551-7